肿瘤免疫治疗技术与产品开发的现状与发展建议

发布时间：2019-05-22 19:07

【摘要】：近年来,肿瘤免疫治疗研究取得了突破性进展,相关技术与产品研发呈爆发式增长,众多生物技术公司和制药公司纷纷投入其中,国际竞争日趋激烈。未来我国如何能够抓住机遇,在国际竞争中脱颖而出是当前亟待思考的问题。通过对肿瘤疫苗,以CAR-T和TCR-T为代表的过继细胞疗法和以PD-1/PD-L1靶点为核心的免疫检查点抗体及药物研究的主要产品、技术和研究方向的全面梳理,加深对本领域发展现状的整体把握。通过分析上述代表性肿瘤免疫疗法的技术特点和发展趋势,为研发工作提供参考,同时针对我国在该领域的研发现状与存在的问题,提出加强统筹规划、注重基础研究、重视专利保护以及加强科学监管的发展建议,为如何更好的发展我国肿瘤免疫治疗领域提供参考意见。
[Abstract]:In recent years, tumor immunotherapy research has made a breakthrough, related technology and product research and development has shown explosive growth, many biotechnology companies and pharmaceutical companies have invested in it, the international competition is becoming increasingly fierce. How to seize the opportunity in the future and stand out in the international competition is an urgent problem to be considered at present. Through the comprehensive combing of the main products, techniques and research directions of tumor vaccines, adoptive cell therapy represented by CAR-T and TCR-T, and immune checkpoint antibodies and drug research with PD-1/PD-L1 targets as the core, Deepen the overall grasp of the current situation of development in this field. By analyzing the technical characteristics and development trend of the representative tumor immunotherapy mentioned above, this paper provides a reference for the research and development work, and puts forward strengthening the overall planning and paying attention to the basic research in view of the present situation and existing problems of the research and development in this field in our country. The development suggestions of paying attention to patent protection and strengthening scientific supervision provide reference suggestions for how to better develop the field of tumor immunotherapy in China.
【作者单位】：中国生物技术发展中心;
【分类号】：R730.51

【参考文献】